Skip to content

REspectful CAring for the AGitated Elderly

REspectful CAring for the AGitated Elderly. How to Best Meet the Needs of People With Dementia With Severe Behavioural Disturbances. Toward a Respectful and Cost-effective Model

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03507504
Acronym
RECAGE
Enrollment
500
Registered
2018-04-25
Start date
2018-04-19
Completion date
2021-12-31
Last updated
2019-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dementia

Keywords

psychiatric aspects

Brief summary

The treatment of Behavioural and Psychological Symptoms of Dementia (BPSD) continue to raise difficult problems. Both the pharmacologic and non-pharmacologic therapies often fail to achieve the expected results. The aim of this study is to assess the short- and long-term efficacy of an intervention, the Special Care Unit for patients with BPSD (SCU-B), already implemented in some countries but not validated so far, as well as its cost-effectiveness

Detailed description

Two cohorts of 250 patients each will be recruited by six clinical centres endowed with a SCU-B (one cohort) and six centres lacking this structure. The follow-up will last 3 years, during which patients will be visited every 6 months and submitted to a battery exploring the severity of the BPSD and the quality of life. All adverse events will be registered, as well as some anticipated occurrences (admissions to the general hospital for intercurrent diseases, admissions to a SCU-B pertaining to the clinical participating centre and, if any, admissions to a SCU-B not pertaining to the Consortium member, nursing home placement). At the same time the quality of life of the primary caregivers will be measured, as well as their attitude toward dementia. A cost-effectiveness analysis will be performed comparing the cohorts. Finally the time to the nursing home placement will be recorded and compared between the two cohorts

Interventions

OTHERSCU-B

SCU-B is a residential medical structure lying outside of a nursing home, in a general hospital or elsewhere, e.g. in a private hospital, where patients with BPSD are temporarily admitted when their behavioural disturbances are not amenable to control at home.

Sponsors

Mediolanum Cardio Research
CollaboratorOTHER
Fondazione Europea di Ricerca Biomedica Ferb Onlus
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* diagnosis of primary dementia (DSM IV) * MMSE score ≤ 24 * NPI global score ≥ 32/144 * a caregiver (informal/family member or formal caregiver) who commits her/himself to accompany the patient along the three-year course of the study * living at home (nursing home residents are excluded).

Exclusion criteria

* presence of uncontrolled medical disease potentially contributing to the cognitive decline and BPSD * concomitant psychiatric disorders or chronic alcoholism * concomitant diseases severe enough to reduce life expectancy \< 6 months

Design outcomes

Primary

MeasureTime frameDescription
change of BPSDbaseline, 6, 12, 18, 24, 30, 36 monthsNeuropsychiatric Inventory (NPI), range 0-144

Secondary

MeasureTime frameDescription
quality of life of patientsbaseline, 6, 12,18, 24, 30, 36 monthsQuality of Life Alzheimer's Disease (QoL-AD), range 0-52
quality of life of caregiversbaseline, 6, 12, 18, 24, 30, 36 monthsCaregiver Burden Inventory (CBI), range 0-96
cost-effectiveness of SCU-Bbaseline, 6, 12, 18, 24, 30, 36 monthsResource Utilisation in Dementia (RUD)

Other

MeasureTime frameDescription
delayed institutionalisationuntil 3 yearsTime to nursing home placement

Countries

Belgium, France, Germany, Greece, Italy, Norway, Switzerland

Contacts

Primary ContactCarla Finocchiaro, Ph.D.
carla.finocchiaro@cf-c.it+390231083323
Backup ContactSara Fascendini, M.D.
recage@ferbonlus.com+390353065206

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026